Beaton Management Co. Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 4.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,755 shares of the company’s stock after selling 1,120 shares during the period. Johnson & Johnson makes up approximately 2.8% of Beaton Management Co. Inc.’s investment portfolio, making the stock its 5th biggest position. Beaton Management Co. Inc.’s holdings in Johnson & Johnson were worth $3,388,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in JNJ. Newfound Research LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $28,000. Essex Investment Management Co. LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $37,000. Islay Capital Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $42,000. FAI Wealth Management boosted its position in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after buying an additional 101 shares during the period. Finally, HWG Holdings LP purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $49,000. Institutional investors and hedge funds own 67.44% of the company’s stock.
NYSE:JNJ opened at $144.68 on Tuesday. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The firm has a market cap of $380.88 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 3.04 and a beta of 0.69. The firm’s fifty day moving average is $144.85 and its two-hundred day moving average is $146.39.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same period in the prior year, the company earned $2.12 earnings per share. The firm’s revenue was up 1.7% on a year-over-year basis. As a group, equities research analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s payout ratio is currently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
A number of analysts recently issued reports on the company. Credit Suisse Group boosted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Cantor Fitzgerald upped their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday, November 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $164.93.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Insider Trading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.